Novartis Comes to the Rescue of Xoma with TGFb Antibody Licensing Deal
By Heather Cartwright & Keshav Mahawar
Pharma Deals Review: Vol 2015 Issue 10 (Table of Contents)
Published: 30 Oct-2015
DOI: 10.3833/pdr.v2015.i10.2129 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In another move to strengthen and broaden its immuno-oncology pipeline, Novartis has in-licensed Xoma’s anti-transforming growth factor-beta (TGFb) antibody programme in a deal potentially worth up to US$517 M, including an upfront payment of US$37 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS